Literature DB >> 17712099

Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample.

Peijun Chen1, Helen C Kales, Daniel Weintraub, Frederic C Blow, Lan Jiang, Alan M Mellow.   

Abstract

We examined the impact of comorbid Parkinson's disease (PD) on depression treatment. Using national Veterans Affairs (VA) databases, fiscal year 2002 data were examined for 283 273 elderly males seen for depression. We compared 2 matched depression groups, one with (N = 7868) and one without (N = 7868) PD. In the 12-month period following a depression-related clinic visit, PD and non-PD patients were equally likely to fill an antidepressant prescription (77.8% vs. 77.4%), most commonly for a selective serotonin re-uptake inhibitor (SSRI) (62.9% vs 62.6%). Depressed PD patients had slightly higher rates of newer non-SSRI use (20.6% vs 19.2%, P < .05) and lower rates of tricyclic antidepressant use (7.4% vs 8.9%, P < .001). The presence of a PD diagnosis appears to have little impact on the frequency and type of antidepressant treatment. Efforts to improve the care of depressed PD patients should focus instead on improving recognition, ensuring adequacy of treatment, and evaluating the efficacy of existing antidepressants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712099      PMCID: PMC2001165          DOI: 10.1177/0891988707301866

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  16 in total

Review 1.  Depression and Parkinson's disease: a review.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  1992-04       Impact factor: 18.112

Review 2.  Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease.

Authors:  J R Slaughter; K A Slaughter; D Nichols; S E Holmes; M P Martens
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

3.  Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial.

Authors:  Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

4.  Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

Authors:  I H Richard; R Kurlan; C Tanner; S Factor; J Hubble; O Suchowersky; C Waters
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

5.  The relationship of serotonin to depression in Parkinson's disease.

Authors:  R Mayeux; Y Stern; M Sano; J B Williams; L J Cote
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

6.  The quality of life in Parkinson's disease.

Authors:  A M Kuopio; R J Marttila; H Helenius; M Toivonen; U K Rinne
Journal:  Mov Disord       Date:  2000-03       Impact factor: 10.338

7.  A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease.

Authors:  S E Starkstein; H S Mayberg; R Leiguarda; T J Preziosi; R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

8.  Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Am Geriatr Soc       Date:  2004-05       Impact factor: 5.562

9.  Recognition and treatment of depression in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-09       Impact factor: 2.680

10.  Evaluation of the adequacy of outpatient antidepressant treatment.

Authors:  Jeffrey B Weilburg; Kathleen M O'Leary; James B Meigs; John Hennen; Randall S Stafford
Journal:  Psychiatr Serv       Date:  2003-09       Impact factor: 3.084

View more
  14 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Using Canadian Primary Care Sentinel Surveillance Network data to examine depression in patients with a diagnosis of Parkinson disease: a retrospective cohort study.

Authors:  Kimberly Rose P Singian; Morgan Price; Vicky Bungay; Sabrina T Wong
Journal:  CMAJ Open       Date:  2016-08-08

3.  Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Brian F Daley; Timothy J Collier
Journal:  Exp Neurol       Date:  2015-02-12       Impact factor: 5.330

4.  Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?

Authors:  Laura B Zahodne; Oscar Bernal-Pacheco; Dawn Bowers; Herbert Ward; Genko Oyama; Natlada Limotai; Frances Velez-Lago; Ramon L Rodriguez; Irene Malaty; Nikolaus R McFarland; Michael S Okun
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

Review 5.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

6.  A controlled trial of antidepressants in patients with Parkinson disease and depression.

Authors:  M Menza; R D Dobkin; H Marin; M H Mark; M Gara; S Buyske; K Bienfait; A Dicke
Journal:  Neurology       Date:  2008-12-17       Impact factor: 9.910

Review 7.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

Review 8.  Beyond tremor and rigidity: non-motor features of Parkinson's disease.

Authors:  Matthias Löhle; Alexander Storch; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2009-08-14       Impact factor: 3.575

Review 9.  Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.

Authors:  Matteo Vismara; Beatrice Benatti; Gregorio Nicolini; Ilaria Cova; Edoardo Monfrini; Alessio Di Fonzo; Vincenza Fetoni; Caterina A Viganò; Alberto Priori; Bernardo Dell'Osso
Journal:  BMC Neurol       Date:  2022-05-05       Impact factor: 2.903

Review 10.  Management of Depression in Parkinson's Disease: A Systematic Review.

Authors:  Sergio E Starkstein; Simone Brockman
Journal:  Mov Disord Clin Pract       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.